Anti-nerve growth factor monoclonal antibodies

spotlight topic:

Published 10 September 2025

Webster, R.P., Anderson, G.I. and Gearing, D.P. (2014) Canine Brief Pain Inventory scores for dogs with osteoarthritis before and after administration of a monoclonal antibody against nerve growth factor. American Journal of Veterinary Research, 75 (6), pp. 532-535. https://doi.org/10.2460/ajvr.75.6.532
Lascelles, B.D.X. et al. (2015) A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain. BMC Veterinary Research, 11, no. 101. https://doi.org/10.1186/s12917-015-0413-x
Corral, M.J. et al. (2021) A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Veterinary Anaesthesia and Analgesia, 48 (6), pp. 943-955. https://doi.org/10.1016/j.vaa.2021.08.001
An inFOCUS summary of this article is available

Krautmann, M. et al. (2021) Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. The Veterinary Journal, 276, 105733. https://doi.org/10.1016/j.tvjl.2021.105733.An inFOCUS summary of this article is available

Michels, G.M. et al. (2023) A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody. Veterinary Anaesthesia and Analgesia, 50 (5), pp. 446-458. https://doi.org/10.1016/j.vaa.2023.06.003
Innes, J.F. et al. (2025) A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. Frontiers in Veterinary Science, 12, 1502218. https://doi.org/10.3389/fvets.2025.1502218
Gildea, E. et al. (2024) Use of Bedinvetmab (Librela®) for canine osteoarthritis in France, Germany, Italy, Spain, and the UK: Quantitative analysis of veterinarian satisfaction and real-world treatment patterns. Animals, 14 (15), 2231. https://doi.org/10.3390/ani14152231
Reid, J. et al (2024) Measuring the effect of the anti-nerve growth factor antibodies bedinvetmab and frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study. Frontiers in Veterinary Science, 11, 1395360. https://doi.org/10.3389/fvets.2024.1395360

Published 10 September 2025

Gruen, M.E. et al. (2016) A feline‐specific anti‐nerve growth factor antibody improves mobility in cats with degenerative joint disease–associated pain: A pilot proof of concept study.Journal of Veterinary Internal Medicine, 30 (4), pp. 1138-1148. https://doi.org/10.1111/jvim.13972
Gruen, M.E. et al. (2021) Frunevetmab, a felinized anti‐nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats.Journal of Veterinary Internal Medicine, 35 (6), pp.2752-2762. https://doi.org/10.1111/jvim.16291
Gruen, M.E., Myers, J.A. and Lascelles, B.D.X. (2021) Efficacy and safety of an anti-nerve growth factor antibody (frunevetmab) for the treatment of degenerative joint disease-associated chronic pain in cats: a multisite pilot field study. Frontiers in Veterinary Science, 8, 610028. https://doi.org/10.3389/fvets.2021.610028
An inFOCUS summary of this article is available

Reid, J. et al (2024) Measuring the effect of the anti-nerve growth factor antibodies bedinvetmab and frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study. Frontiers in Veterinary Science, 11, 1395360. https://doi.org/10.3389/fvets.2024.1395360
Wright, A. et al. (2024) Pet owners’ preferences for quality of life improvements and costs related to innovative therapies in feline pain associated with osteoarthritis – A quantitative survey. Animals, 14 (16), 2308. https://doi.org/10.3390/ani14162308

Claiming CPD for reading inFOCUS articles

Reading and reflecting on articles can count towards your CPD, and we have a template to help you with the process.

Online full-text available to Library members

A range of library membership packages is available and MRCVS vets and RVNs can join the library for a heavily subsidised, annual fee.

Anti-nerve growth factor monoclonal antibodies – Efficacy